Proteolysis Resistant Active VEGF
AssigneeBayer Innovation GmbH
InventorsSabine Eming, Thomas Krieg, Stephan Sollberg, Gereon Lauer
Life of this patent
Estimating the term…
Abstract
The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.
Claims16
-16. (canceled)
A method for inhibiting plasmin, inducing neoangiogenesis, and/or inhibiting matrix degradation comprising administering to a patient in need thereof an effective amount of a VEGF variant comprising:
- an amino acid sequence, wherein said amino acid sequence is the amino acid sequence of a native vascular endothelial growth factor in which at least one amino acid at positions 110 or 111 of the native vascular endothelial growth factor is replaced by proline or is deleted, wherein plasmin is inhibited, neoangiogenesis is induced and/or matrix degradation is inhibited.
Dependencies are inferred from the claim text.